Use of antiepileptic drugs in hepatic and renal disease

Handbook of Clinical Neurology

Volumn 119, Issue , 2014, Pages 417-432

  Asconapé, Jorge J ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Anticonvulsants; Epilepsy; Hemodialysis; Hepatic failure; Peritoneal dialysis; Pharmacokinetics; Renal failure

Indexed keywords

ANTICONVULSIVE AGENT;

ARTICLE; CHEMICALLY INDUCED DISORDER; EPILEPSY; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LIVER FAILURE; PERITONEAL DIALYSIS; PHARMACOKINETICS; TOXIC HEPATITIS;

ANTICONVULSANTS; EPILEPSY; HEMODIALYSIS; HEPATIC FAILURE; PERITONEAL DIALYSIS; PHARMACOKINETICS; RENAL FAILURE;

ANTICONVULSANTS; DRUG-INDUCED LIVER INJURY; EPILEPSY; HUMANS; KIDNEY DISEASES;

EID: 84890885632     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-7020-4086-3.00027-8     Document Type: Chapter

References (100)

1. Adkins J.C., Noble S. Tiagabine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998, 55:437-460.
2. Adler D.S., Martin E., Gambertoglio J.G., et al. Hemodialysis of phenytoin in a uremic patient. Clin Pharmacol Ther 1975, 18:65-69.
3. Affrime M., Reidenberg M.M. The protein binding of some drugs in plasma from patients with alcoholic liver disease. Eur J Clin Pharmacol 1975, 8:267-269.
4. Ahmed S.N., Siddiqui Z.A. Antiepileptic drugs and liver disease. Seizure 2006, 15:156-164.
5. Almeida L., Soares-da-Silva P. Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs R D 2003, 4:269-284.
6. Almeida L., Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 2007, 4:88-96.
7. Almeida L., Falcao A., Maia J., et al. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005, 45:1062-1066.
8. Almeida L., Potgieter J.H., Maia J., et al. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 2008, 64:267-273.
9. Alvin J., McHorse T., Hoyumpa A., et al. The effect of liver disease in man on the disposition of phenobarbital. J Pharmacol Exp Ther 1975, 192:224-235.
10. Asconapé J., D'Souza J. No dose adjustments of oxcarbazepine required in mild or moderate hepatically impaired patients. Epilepsia 2004, 45(Suppl. 7):305.
11. Asconapé J.J., Penry J.K. Use of antiepileptic drugs in the presence of liver and kidney diseases: a review. Epilepsia 1982, 23(Suppl. 1):S65-S79.
12. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004, 45(Suppl. 6):13-18.
13. Blackburn-Munro G., Dalby-Brown W., Mirza N.R., et al. Retigabine: chemical synthesis to clinical application. CNS Drug Rev 2005, 11:1-20.
14. Blaschke T.F., Meffin P.J., Melmon K.L., et al. Influence of acute viral hepatitis on phenytoin kinetics and protein binding. Clin Pharmacol Ther 1975, 17:685-691.
15. Blum R.A., Sica D.A., Comstock T.J., et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 1994, 58:154-159.
16. Bochner F., Hooper W.D., Sutherland J.M., et al. The renal handling of diphenylhydantoin and 5(p-hydroxyphenyl)-5-phenyl-hydantoin. Clin Pharmacol Ther 1973, 14:791-796.
17. Borga O., Hoppel C., Odar-Cederlöf I., et al. Plasma levels and renal excretion of phenytoin and its metabolites in patients with renal failure. Clin Pharmacol Ther 1979, 26:306-314.
18. Boston Collaborative Drug Surveillance Program Diphenylhydantoin side effects and serum albumin levels. Clin Pharmacol Ther 1973, 14:529-532.
19. Britzi M., Perucca E., Soback S., et al. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia 2005, 46:378-384.
20. Bruni J., Wang L.H., Marbury T.C., et al. Protein binding of valproic acid in uremic patients. Neurology 1980, 30:557-559.
21. Buchanan R.A., Kinkel A.W., Smith T.C. The absorption and excretion of ethosuximide. Int J Clin Pharmacol 1973, 7:213-218.
22. Buchanan R., Bockbrader H., Chang T., et al. Single- and multiple-dose pharmacokinetics of zonisamide. Epilepsia 1996, 37(Suppl. 5):172.
23. Butler T.C. The metabolic conversion of 5,5-diphenylhydantoin to 5(p-hydroxyphenyl)-5 phenyl-hydantoin. J Pharmacol Exp Ther 1957, 119:1-11.
24. Cato A., Gustavson L.E., Qian J.X., et al. Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine. Epilepsia 1998, 39:43-47.
25. Cawello W., Kropeit D., Schiltmeyer B., et al. Food does not affect the pharmacokinetics of SPM-927 (Abstract). Epilepsia 2004, 45(Suppl. 7):307.
26. Chetty M., Sarkar P., Aggarwal A., et al. Carbamazepine poisoning treatment with haemodialysis. Nephrol Dial Transplant 2003, 18:220-221.
27. Dasgupta A., Jacques M., Malhotra D. Diminished protein binding capacity of uremic sera for valproate following hemodialysis: the role of free fatty acids and uremic compounds. Am J Nephrol 1996, 16:327-333.
28. Depner T.A., Gulyassy P.F. Plasma protein binding in uremia: extraction and characterization of an inhibitor. Kidney Int 1980, 18:86-94.
29. Dickins M., Chen C. Lamotrigine: chemistry, biotransformation and pharmacokinetics. Antiepileptic Drugs 2002, 370-379. Lippincott, Williams and Wilkins, Philadelphia. 5th edn. R.H. Levy, R.H. Mattson, B.S. Meldrum (Eds.).
30. Dromgoole S.H. The effect of haemodialysis on the binding capacity of albumin. Clin Chim Acta 1973, 46:469-472.
31. Fillastre J.P., Taburet A.M., Fialaire A., et al. Pharmacokinetics of lamotrigine in patient with renal impairment: influence of haemodialysis. Drugs Exp Clin Res 1993, 19:25-32.
32. French J. Use of levetiracetam in special populations. Epilepsia 2001, 42(Suppl. 4):40-43.
33. Frenchie D., Bastani B. Significant removal of phenytoin during high flux dialysis with cellulose triacetate dialyzer. Nephrol Dial Transplant 1998, 13:817-818.
34. Glue P., Sulowicz W., Colucci R., et al. Single-dose pharmacokinetics of felbamate in patient with renal dysfunction. Br J Clin Pharmacol 1997, 44:91-93.
35. Grant S.M., Heel R.C. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991, 4:889-926.
36. Gugler R., Azarnoff D.L. Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet 1976, 1:25-35.
37. Gugler R., von Unruh G.E. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1980, 5:67-83.
38. Gugler R., Shoeman D.W., Huffman D.H., et al. Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest 1975, 55:1182-1183.
39. Gulyassy P.F., Bottini A.T., Jarrard E.A., et al. Isolation of inhibitors of ligand: albumin-binding from uremic body fluids and normal urine. Kidney Int 1983, 24(Suppl. 16):S238-S242.
40. Haegele K.D., Huebert N.D., Ebel M., et al. Pharmacokinetics of vigabatrin: implications of creatinine clearance. Clin Pharmacol Ther 1988, 44:558-565.
41. Hainzl D., Parada A., Soares-da-Silva P. Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res 2001, 44:197-206.
42. Heipertz R., Guthoff A., Bernhardt W. Primidone metabolism in renal insufficiency and acute intoxication. J Neurol 1979, 221:101-104.
43. Hermann R., Ferron G.M., Erb K., et al. Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 2003, 73:61-70.
44. Hooper W.D., Bochner F., Eadie M.J., et al. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther 1974, 15:276-282.
45. Hooper D.W., Dubetz D.K., Bochner F., et al. Plasma protein binding of carbamazepine. Clin Pharmacol Ther 1975, 17:433-440.
46. Hovinga C.A. SPM-927 (Schwarz Pharma). IDrugs 2003, 6:479-485.
47. Ijiri Y., Fukuda F., Suzuki K., et al. Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis. Epilepsia 2004, 45:924-927.
48. Israni R.K., Kasbekar N., Haynes K., et al. Use of antiepileptic drugs in patients with kidney disease. Semin Dial 2006, 19:408-416.
49. Kandrotas R.J., Love J.M., Gal P., et al. The effect of hemodialysis and hemoperfusion on serum valproic acid concentration. Neurology 1990, 40:1456-1458.
50. Kane S.L., Constantiner M., Staubus A.E., et al. High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose. Ann Pharmacother 2000, 34:1146-1151.
51. Kielstein J.T., Schwarz A., Arnavaz A., et al. High-flux hemodialysis: an effective alternative to hemoperfusion in the treatment of carbamazepine intoxication. Clin Nephrol 2002, 57:484-486.
52. Kielstein R.J., Woywodt A., Schumann G., et al. Efficiency of high-flux hemodialysis in the treatment of valproic acid intoxication. J Toxicol Clin Toxicol 2003, 41:873-876.
53. Kinniburgh D.W., Boyd N.D. Isolation of peptides from uremic plasma that inhibit phenytoin binding to plasma proteins. Clin Pharmacol Ther 1981, 30:276-280.
54. Klotz U., Rapp T., Muller W.A. Disposition of valproic acid in patients with liver disease. Eur J Clin Pharmacol 1978, 13:55-60.
55. Kutt H., Winters W., Scherman R., et al. Diphenylhydantoin and phenobarbital toxicity. The role of liver disease. Arch Neurol 1964, 11:649-656.
56. Lacerda G., Krummel T., Sabourdy C., et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006, 67(Suppl. 4):S28-S33.
57. Lau A.H., Gustavson L.E., Sperelakis R., et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997, 38:445-451.
58. Lee C.S., Wang L.H., Marbury T.C., et al. Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis. Clin Toxicol 1980, 17:429-438.
59. Lee C.S., Marbury T.C., Perchalski R.T., et al. Pharmacokinetics of primidone elimination in uremic patients. J Clin Pharmacol 1982, 22:301-308.
60. Leppik I.E. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004, 13(Suppl. 1):S5-S9.
61. Letter J.M., Mellk H., Louis S., et al. Diphenylhydantoin metabolism in uremia. N Engl J Med 1971, 285:648-652.
62. Lloyd P., Flesch G., Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994, 35(Suppl. 3):S10-S13.
63. Lunde P.K.M., Rane A., Yaffee S.J., et al. Plasma protein binding of diphenylhydantoin in man: interaction with other drugs and the effect of temperature and plasma dilution. Clin Pharmacol Ther 1970, 11:846-855.
64. McAuliffe J.J., Sherwin A.L., Leppik I.E., et al. Salivary levels of anticonvulsants: a practical approach to drug monitoring. Neurology 1977, 27:409-413.
65. McLean M.J. Clinical pharmacokinetics of gabapentin. Neurology 1994, 44(Suppl. 5):S17-S22.
66. Maia J., Almeida L., Falcao A., et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 2008, 46:119-130.
67. Marbury T.C., Lee C.C., Perchalski R.J. Hemodialysis clearance of ethosuximide in patients with chronic renal failure. Am J Hosp Pharm 1981, 38:1757-1760.
68. Marquardt E.D., Ishisaka D.Y., Barra K.K., et al. Removal of ethosuximide and phenobarbital by peritoneal dialysis in a child. Clin Pharm 1992, 11:1030-1031.
69. Martin E., Gambertoglio J.G., Adler D.S., et al. Removal of phenytoin by hemodialysis in uremic patients. JAMA 1977, 238:1750-1753.
70. Mauro L.S., Mauro V.F., Bachmann K.S., et al. Accuracy of two equations in determining normalized phenytoin concentrations. DICP 1989, 23:64-68.
71. Odar-Cederlöf I., Lunde P., Sjoqvist F. Abnormal pharmacokinetics of phenytoin in a patient with uraemia. Lancet 1970, 2:831.
72. Odar-Cederlöf I., Borga O. Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding. Eur J Clin Pharmacol 1974, 7:31-37.
73. Olsen G.D., Bennett W.M., Porter G.A. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure. Clin Pharmacol Ther 1975, 17:677-684.
74. Palmer B.F. Effectiveness of hemodialysis in the extracorporeal therapy of phenobarbital overdose. Am J Kidney Dis 2000, 36:640-643.
75. Palmer K.J., McTavisk D. Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993, 45:1041-1065.
76. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004, 43:707-724.
77. Perucca E., Cloyd J., Critchley D., et al. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008, 49:1123-1141.
78. Plosker G.L., Scott L.J. Retigabine in partial seizures. CNS Drugs 2006, 20:601-608.
79. Porto I., John E.G., Heilliezer J. Removal of phenobarbital during continuous cycling peritoneal dialysis in a child. Pharmacotherapy 1997, 17:832-835.
80. Posner J., Cohen A.F., Land G., et al. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinemia. Br J Clin Pharmacol 1989, 28:117-120.
81. Radtke R.A. Pharmacokinetics of levetiracetam. Epilepsia 2001, 42(Suppl. 4):24-27.
82. Randinitis E.J., Posvar E.L., Alvey C.W., et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003, 43:277-283.
83. Rane A., Lunde P.K.M., Jalling B., et al. Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants. J Pediatr 1971, 78:877-882.
84. Reidenberg M.M., Affrime M. Influence of disease on binding of drugs to plasma proteins. Ann N Y Acad Sci 1973, 226:115-126.
85. Reidenberg M.M., Drayer D.E. Effects of renal disease upon drug disposition. Drug Metab Rev 1978, 8:293-302.
86. Reidenberg M.M., Odar-Cederlöf I., Von Bahr C., et al. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med 1971, 285:264-267.
87. Rouan M.C., Lecaillon J.B., Godbillon J., et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 1994, 47:161-167.
88. Schuerer D.J., Brophy P.D., Maxvold N.J., et al. High-efficiency dialysis for carbamazepine overdose. J Toxicol Clin Toxicol 2000, 38:321-323.
89. 14] felbamate in healthy men. Epilepsia 1990, 31:642.
90. Steele W.W.H., Lawrence J.R., Elliot H.L., et al. Alterations of phenytoin protein binding with in vivo haemodialysis in dialysis encephalopathy. Eur J Clin Pharmacol 1979, 15:69-71.
91. Stern E.L. Possible phenylethylmalondiamide (PEMA) intoxication. Ann Neurol 1977, 2:356-357.
92. Streete J.M., Berry D.J., Jones J.A., et al. Clearance of phenylethylmalonamide during haeamodialysis of a patient with renal failure. Ther Drug Monit 1990, 12:281-283.
93. Tang B.K., Inaba T., Kalow W. N-hydroxyphenobarbital. The major metabolite of phenobarbital in man. Fed Proc 1977, 36:966.
94. Tapolyai M., Campbell M., Dailey K., et al. Hemodialysis is as effective as hemoperfusion for drug removal in carbamazepine poisoning. Nephron 2002, 90:213-215.
95. Tiula E., Haapanen E.J., Neuvonen P.J. Factors affecting serum protein binding of phenytoin, diazepam and propranolol in acute renal diseases. Int J Clin Pharmacol Ther Toxicol 1987, 25:469-475.
96. Van Peer A.P., Belpaire F.M., Rosseel M.T., et al. Distribution of antipyrine, phenylbutazone, and phenytoin in experimental renal failure. Pharmacology 1981, 22:139-145.
97. Vanholder R., Van Landschoot N., De Smet R., et al. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int 1988, 33:996-1004.
98. Wong M.O., Eldon M.A., Keane W.F., et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol 1995, 35:622-626.
99. Wootton R., Soul-Lawton J., Rolan P.E., et al. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br J Clin Pharmacol 1997, 43:23-27.
100. Zawada E.T., Nappi J., Done G., et al. Advances in the hemodialysis management of phenobarbital overdose. South Med J 1983, 76:6-8.